EXPERIMENTAL STUDY: MANAGEMENT OF METISOPRINOL IN PATIENTS WITH COVID-19
PDF (Español (España))
HTML (Español (España))

Keywords

COVID-19
SARS-CoV-2
metisoprinol

How to Cite

BorgesM., BorgesM., BorgesJ., & BastidasR. (2020). EXPERIMENTAL STUDY: MANAGEMENT OF METISOPRINOL IN PATIENTS WITH COVID-19. Universidad Ciencia Y Tecnología, 24(103), 41-50. https://doi.org/10.47460/uct.v24i103.356

Abstract

Covid-19 is a disease characterized by presenting acute respiratory distress syndrome and multi-system dysfunction. The present randomized controlled clinical trial of experimental design was carried out in order to demonstrate the efficacy of metisoprinol in the alternative antiviral management of covid 19, in view of the fact that there is no proven effective treatment in the current global pandemic decreed by the WHO. A population of 60 patients, distributed in groups of 30 (experimental group and a control group) of any age and sex with controlled comorbidities, who presented signs and symptoms of SARS-CoV-2 and S02 greater than 90% breathing air, was evaluated. environment in a clinical phase of less than 15 days attended at home medical consultation in the city of Guayaquil, Ecuador between the period of March and April 2020. This study was developed to determine a pilot protocol that generates fewer adverse effects, avoiding medical complications in symptomatic patients and reverse the clinical and imaging picture. The almost null possibility of persisting signs and symptoms was demonstrated by calculation of relative risk, as well as the presence of lung lesions in imaging controls in 03.33% and 10% rRT-PCR reactivity treated with metisoprinol.

Keywords: COVID-19, SARS-CoV-2, Metisoprinol.

References

[1]“Interpretación de las pruebas diagnósticas frente a sars-cov-2”, Instituto de Salud Carlos III, ponencia, versión 2, 2020.

[2]X.Yang, Y.Yu, J.Xu, S. Huaging, X. Jia'an, L.Hong, et al, “Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study”. The Lancet Respiratory Medicine, Vol 8. pp. 475-481, May 2020.

[3]D.Wang, B.Hu, C.Hu, et al, “Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China”. JAMA, Vol.323, 11, pp. 1061–1069, March 2020.

[4]“Protocolo de investigación de los primeros casos y sus contactos directos (FFX) de la enfermedad por Coronavirus 2019 (COVID-19)”, Organización Mundial de la Salud, versión 2, 2020.

[5]“Manejo clínico del COVID-19: atención hospitalaria”, Ministerio de Sanidad Gobierno de España, documento técnico, 2020.

[6]L. Baden, and E. Rubin, “Covid-19 - The Search for Effective Therapy.” The New England journal of medicine, vol. 382, 19, pp.1851-1852, March 2020.

[7]B. Cao, Y. Wang, D. Wen, et al, “A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19”, The New England journal of medicine, vol. 382, 19, pp.1787-1799.

[8]“Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)”, World health Organization, report, 2020.

[9]S. Mallapaty, “Mystery deepens over animal source of coronavirus”, Nature, vol. 579, pp.18-19, March 2020.

[10]TT. Lam, N. Jia, YW. Zhang, et al, “Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins”, Nature, March 2020.

https://doi.org/10.47460/uct.v24i103.356
PDF (Español (España))
HTML (Español (España))

Downloads

Download data is not yet available.